A prospective validation of two cutoff levels ( 0.03 microg/L and 0.01 microg/L ) was performed in 7115 patients with non-ST-elevation acute coronary syndrome from the Global Utilization of Strategies To open Occluded arteries IV ( GUSTO-IV ) trial .
